MedTrace Logo

Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics

NCT04305821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2023-04-12

No results posted yet for this study

Summary

Head trauma is a common injury in emergency department. Investigation to search for complication is guided by the clinical examination and the case history, such as taking anti-thrombotics. Cranial computed tomography (CCT) is the gold standard to investigate, and is mandatory in case of antithrombotic drugs.

Recently, some biomarkers have proven their utility to rule-out mild head trauma without CCT in the general population. Among these biomarkers, S100β protein has been added in guidelines for mild head trauma. Some studies have found similar data in population taking anticoagulant or antiplatelet drugs.

The investigators aim to prove medical utility of S100β protein in population under antithrombotics, by the reduction of CCT use. Then, The investigators hypothesize that the add of S100β protein reduces cost of health care in the management of head injury in that population.

Conditions

  • Mild Head Injury
  • Anticoagulant
  • Antiplatelet

Interventions

OTHER

Dosage of S100β protein

Dosage of S100β protein

Sponsors & Collaborators

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Cédric GANGLOFF, MD · Centre Hospitalier Univesitaire de Rennes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-09
Primary Completion
2021-09-20
Completion
2021-09-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04305821 on ClinicalTrials.gov